United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma

被引：1
|
作者：
Davies, F. [1 ]
Morris, C. [2 ]
Bird, J. [3 ]
Cook, G.
Williams, C. [4 ]
Tighe, J. [5 ]
Cavenagh, J. [6 ]
Behrens, J. [7 ]
Schey, S. [8 ]
Morgan, G. [1 ]
机构：
[1] Royal Marsden Hosp, Sutton SM2 5NG, Surrey, England
[2] Belfast City Hosp, Belfast BT9 7AD, Antrim, North Ireland
[3] Bristol Haematol & Oncol Ctr, Bristol, Avon, England
[4] City Hosp Nottingham, Nottingham, England
[5] Aberdeen Royal Infirm, Aberdeen, Scotland
[6] St Bartholomews Hosp, London, England
[7] Epsom & St Helier Hosp, Surrey, England
[8] Kings Coll Hosp London, London, England
来源：
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY | 2009年 / 31卷 / 02期
关键词：
Myeloma; lenalidomide; UKMF; relapse therapy; THALIDOMIDE PLUS DEXAMETHASONE; HIGH-DOSE DEXAMETHASONE; COMBINATION THERAPY; DRUG-RESISTANCE; PHASE-III; CHEMOTHERAPY; CYCLOPHOSPHAMIDE; PREDNISONE; MELPHALAN; SURVIVAL;
D O I：
10.1111/j.1751-553X.2008.01106.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Lenalidomide is an immunomodulatory drug, which has anti-myeloma activity in vitro. Phase II clinical trials have demonstrated lenalidomide in combination with dexamethasone is effective for the treatment of both relapsed refractory myeloma and newly diagnosed patients. Two large phase III studies comparing lenalidomide and dexamethasone to dexamethasone alone in relapsed patients showed superiority in response, progression free and overall survival. It is administered orally for 21 days in a 28 day cycle. Side effects are manageable and include neutropenia and venous thrombotic events. It is currently approved, in combination with dexamethasone, for the treatment of multiple myeloma patients who have received at least one prior therapy. Studies in front line patients and with other drug combinations are ongoing. Given the strength of this data the UK Myeloma Forum believe that lenalidomide in combination with dexamethasone should be available for prescription by UK haematologists according to its licensed indication in patients with relapsed myeloma.
引用
收藏
页码：119 / 131
页数：13
相关论文
共 50 条
  • [41] Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma
    Lacy, Martha Q.
    Dispenzieri, Angela
    Gertz, Morie A.
    Greipp, Philip R.
    Gollbach, Kimberly L.
    Hayman, Suzanne R.
    Kumar, Shaji
    Lust, John A.
    Rajkumar, S. Vincent
    Russell, Stephen J.
    Witzig, Thomas E.
    Zeldenrust, Steven R.
    Dingli, David
    Bergsagel, P. Lief
    Fonseca, Rafael
    Reeder, Craig B.
    Stewart, A. Keith
    Roy, Vivek
    Dalton, Robert J.
    Carr, Alan B.
    Kademani, Deepak
    Keller, Eugene E.
    Vilozzi, Christopher V.
    Kyle, Robert A.
    MAYO CLINIC PROCEEDINGS, 2006, 81 (08) : 1047 - 1053
  • [42] Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies
    Joao, Cristina
    Figueiredo, Alfredo
    Martins, Helena Figueira
    CURRENT OPINION IN ONCOLOGY, 2012, 24 : S13 - S20
  • [43] Cytomegalovirus Retinitis Associated with Lenalidomide Use for Multiple Myeloma in an Immunocompetent Patient
    Adams, Matthew K.
    Weng, Christina Y.
    CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2019, 2019
  • [44] Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma
    Anderson, Sarah M.
    Beck, Bradley
    Sterud, Susan
    Lockhorst, Robin
    Ngorsuraches, Surachat
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (04) : 806 - 812
  • [45] Lenalidomide A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma
    Scott, Lesley J.
    Lyseng-Williamson, Katherine A.
    DRUGS, 2011, 71 (05) : 625 - 649
  • [46] European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
    Engelhardt, Monika
    Udi, Josefina
    Kleber, Martina
    Spencer, Andrew
    Rocci, Alberto
    Knop, Stefan
    Bruno, Benedetto
    Bringhen, Sara
    Perez-Simon, Jose A.
    Zweegman, Sonja
    Driessen, Christoph
    Patriarca, Francesca
    Gramatzki, Martin
    Terpos, Evangelos
    Sezer, Orhan
    Kropff, Martin
    Straka, Christian
    Johnsen, Hans E.
    Waage, Anders
    Boegsted, Martin
    Lokhorst, Henk
    Hajek, Roman
    Morgan, Gareth
    Boccadoro, Mario
    Ludwig, Heinz
    Cavo, Michele
    Polliack, Aaron
    Sonneveld, Pieter
    Einsele, Hermann
    Palumbo, Antonio
    LEUKEMIA & LYMPHOMA, 2010, 51 (11) : 2006 - 2011
  • [47] Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Moreau, P.
    Masszi, T.
    Grzasko, N.
    Bahlis, N. J.
    Hansson, M.
    Pour, L.
    Sandhu, I.
    Ganly, P.
    Baker, B. W.
    Jackson, S. R.
    Stoppa, A. -M.
    Simpson, D. R.
    Gimsing, P.
    Palumbo, A.
    Garderet, L.
    Cavo, M.
    Kumar, S.
    Touzeau, C.
    Buadi, F. K.
    Laubach, J. P.
    Berg, D. T.
    Lin, J.
    Di Bacco, A.
    Hui, A. -M.
    van de Velde, H.
    Richardson, P. G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (17): : 1621 - 1634
  • [48] Lenalidomide and bortezomib in multiple myeloma: Influence on osteoclast
    Breitkreutz, I.
    Raab, M. S.
    Vallet, S.
    Hideshima, T.
    Raje, N.
    Chauhan, D.
    Munshi, N.
    Richardson, P.
    Anderson, K. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 131 - 131
  • [49] Recommend maintenance therapy with lenalidomide in multiple myeloma
    Manasanch, Elisabet E.
    SEMINARS IN ONCOLOGY, 2016, 43 (06) : 712 - 713
  • [50] Current therapeutic uses of lenalidomide in multiple myeloma
    Hideshima, T
    Richardson, PG
    Anderson, KC
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (02) : 171 - 179
12345